| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Sep 2026 |
8-K: Other Events
Immix Biopharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Rel... |
| 20 Jul 2026 |
8-K: Other Events
As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Given his short tenure, management believes there is no material effect on the business. |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2026, at the 2026 Annual Meeting of stockholders (the “Annual Meeting”) of Immix Biopharma, Inc. (the “Company”), the Company’s stockholders voted on the following two (2) proposals and votes were cast as described below. Thes... |
| 21 May 2026 |
8-K: Other Events
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 |
| 21 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 |
| 30 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones |
| 25 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
Attention: Ilya Rachman, Chief Executive Officer and Chief Scientific Officer |
| 08 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
Immix Biopharma Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC is acting as representative (the “Rep... |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis |
| 26 Nov 2025 |
8-K: Other Events
We consent to the incorporation by reference in the Registration Statement on Form S-3 (File Number 333-290725) of Immix Biopharma, Inc. of our report dated March 29, 2024 relating to the consolidated financial statements of Immix Biopha... |
| 08 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 5, 2025, by and among Immix Biopharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A attached to this Agreement ... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 20, 2025, at the 2025 Annual Meeting (the “Annual Meeting”) of the stockholders of Immix Biopharma, Inc. (the “Company,” “we,” “our,” or “us”), stockholders representing 20,092,566 shares of the Company’s capital stock entitled t... |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement
Immix Biopharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Citizens JMP Securities, LLC (the “Manager”) as follows: |
| 26 Jul 2024 |
8-K: Other Events
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis |
| 22 Jul 2024 |
8-K: Changes in Registrant's Certifying Accountant
We have read the comments made regarding us in Item 4.01 of Form 8-K of Immix Biopharma, Inc. dated July 17, 2024, and are in agreement with those statements. |
| 14 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the Plan is the Immix Biopharma, Inc. Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent... |
| 20 May 2024 |
8-K: Unregistered Sales of Equity Securities; Other Events
Immix Biopharma, Inc., a Delaware corporation (the “Parent”), hereby certifies that: |
| 06 Feb 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
Titan Partners Group LLC, a division of American Capital Partners, LLC |
Loading...